Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.

Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.

Item
http://www.wikidata.org/entity/Q39011809
Da0324, an inhibitor of nuclear factor-κB activation, demonstrates selective antitumor activity on human gastric cancer cellsMiR-31 Regulates Rho-Associated Kinase-Myosin Light Chain (ROCK-MLC) Pathway and Inhibits Gastric Cancer Invasion: Roles of RhoATargeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancerTumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2.HNRNPC as a candidate biomarker for chemoresistance in gastric cancer.Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapyThe combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer.Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.The novel dithiocarbamate, DpdtC suppresses HER2-overexpressed cancer cells by up-regulating NDRG1 via inactivation of HER2-ERK 1/2 signaling.HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition.Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy
P2860

Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.

Item
http://www.wikidata.org/entity/Q39011809
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Combining trastuzumab and cetu ...... erodimerization and signaling.
@en
Combining trastuzumab and cetu ...... erodimerization and signaling.
@nl
type
label
Combining trastuzumab and cetu ...... erodimerization and signaling.
@en
Combining trastuzumab and cetu ...... erodimerization and signaling.
@nl
prefLabel
Combining trastuzumab and cetu ...... erodimerization and signaling.
@en
Combining trastuzumab and cetu ...... erodimerization and signaling.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Combining trastuzumab and cetu ...... erodimerization and signaling.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P698
P921